Novo's drug candidate, CagriSema, showed weight loss below expectations during a trial, dealing a blow to the company's plans ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed” ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug achieving a 22.7% weight loss at 68 weeks, slightly edging out Lilly’s Zepbound at 22.5%.